Diprovocims: a new and potent class of TLR agonists
US11040959B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 29, 2017 |
| Grant date | Jun 22, 2021 |
| Priority date | — |
| Expiry date | Dec 12, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A diprovocim compound that corresponds in structure to structural Formula V is disclosed, wherein A, W, Z, R1, R2, R3 and R4 (when present) are defined within. A diprovocim compound has immune-adjuvant properties on human and mouse cells in culture and on in vivo immunization of mice. A composition containing a diprovocim and a method of using a compound are also disclosed. The immunostimulatory activity of a diprovocim compound is similar to that of LPS, to which there is no apparent structural similarity. A contemplated compound bears no structural similarity to either the TLR1/TLR2 lipoprotein agonists nor to any other synthetic TLR agonist, and is remarkably easy to prepare and synthetically modify.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.